Essential thrombocytosis (ET), polycythemia vera (PV), and primary myelofibrosis (PM) are BCR-ABL–negative myeloproliferative neoplasms (MPN) with the potential to develop into acute leukemia. The risk of progression is increased by oxidative stress and some genetic mutations. As oxidative stress increases with age, and the median age of patients with ET, PV, and PM is expected to soon pass 65 years, a research team led by Mahmut B. Koyuncu examined oxidative stress parameters in older patients with MPN. Their article, published in Clinical Laboratory, reported that serum ischemia modified albumin (IMA) and thiol levels are significantly changed in older patients with BCR-ABL–negative ...
Myeloproliferative Neoplasms (MPN)
Read the most current news and learn about the latest clinical research on myeloproliferative neoplasms (MPNs). Cancer Nursing Today offers up-to-date information on health-related quality of life in patients with MPNs, COVID-19 outcomes in patients with MPNs, and more. From molecular screening and clinical trials to the psychosocial impact of myeloproliferative neoplasms, learn how MPN care is moving forward.
Advertisement
Latest News
According to Alexander Chan, MD, and colleagues from the Department of Pathology at the Memorial Sloan Kettering Cancer ...
In patients with polycythemia vera (PV), arterial thrombosis (AT) and venous thrombosis (VT) events are common complications ...
Polycythemia vera (PV) is subject to the chronic inflammation commonly observed in other myeloproliferative neoplasms. Recent ...
In a follow-up to the randomized controlled trial APL0406, researchers compared long-term health-related quality of life of ...
A phase I study tested low dose clofarabine with escalating doses of entinostat in adults with Philadelphia ...
A study published in the Journal of Clinical Oncology found that therapy with two doses of imetelstat appears to have ...
Advertisement
Conference Highlights
Advertisement
Advertisement
Popular Stories
Many studies are examining COVID-19's impact on particular subgroups of patients with cancer.
The new data is being used to develop a biomarker tool to predict the efficacy of neoadjuvant pembrolizumab.
Oncology nurses experience stress from many different directions—time pressures, nursing shortages, complex cancer ...
